luResponse to the combination of dabrafenib, trametinib and osimertinib in a patient with EGFR-mutant NSCLC harboring an acquired BRAFV600E mutation

We read with great interest the study by Solassol et al [1]. They reported a successful case of using sequential treatment with dabrafetinib/trametinib and osimertinib in a patient with EGFR exon 19 deletion mutation non-small cell lung cancer [NSCLC] with an acquired BRAFV600E mutation. Notably, in their case, dabrafetinib/trametinib and osimertinib were not administrated concurrently. Here, we reported a patient with EGFR L858R/T790  M NSCLC harboring an acquired BRAFV600E mutation rapidly responded to the concurrently combination of dabrafenib, trametinib and osimertinib after treatment with osimertinib.

Source: Lung Cancer - October 13, 2019 Category: Cancer & Oncology Authors: Fei Zhou, Wencheng Zhao, Xiaoxia Chen, Jie Zhang, Caicun Zhou Source Type: research